Simplify Logo

Full-Time

Clinical Sales Specialist

CS, Washington D.C

Confirmed live in the last 24 hours

Corcept Therapeutics

Corcept Therapeutics

201-500 employees

Develops cortisol modulators for medical conditions

Hardware
Biotechnology

Compensation Overview

$140k - $155kAnnually

Senior, Expert

Washington, DC, USA

Category
Field Sales
Sales & Account Management
Required Skills
Sales
Marketing
Requirements
  • BA/BS or equivalent work experience
  • 5+ years sales experience required, recent endocrine relationships, specialty therapeutic, hospital, or orphan drugs sales experience highly preferred
Responsibilities
  • Build and develop professional relationships with influential high prescribers and thought leaders in the territory to enhance Corcept brand and product loyalty
  • Leverages expertise and knowledge of the therapeutic disease state, the marketplace, applicable competitors, industry, and cross-functional activities/plans to anticipate and effectively manage business opportunities and challenges
  • Develops and implements effective customer specific territory plans and communicates insights to internal stakeholders
  • Prioritizes time and effort to ensure optimal coverage of appropriate physician specialists based on opportunity and potential
  • Plan and participate in education programs and speaker dinner programs
  • Manage territory expenses/budget to support sales and marketing activities

Corcept Therapeutics focuses on developing treatments that regulate cortisol levels in the body, which is important for managing various health issues. Their main product, Korlym, is used to treat Cushing's syndrome, a condition caused by too much cortisol. Korlym was approved by the FDA in 2012 and is the first medication specifically for this disorder. Corcept stands out from competitors by having a strong emphasis on research and development, having discovered over 1,000 unique cortisol modulators. The company aims to expand its range of treatments while also providing educational resources to healthcare professionals and patients to improve understanding and care for cortisol-related conditions.

Company Stage

IPO

Total Funding

$119.1M

Headquarters

Menlo Park, California

Founded

1998

Growth & Insights
Headcount

6 month growth

4%

1 year growth

10%

2 year growth

31%
Simplify Jobs

Simplify's Take

What believers are saying

  • Significant investments from firms like Intrinsic Edge Capital and Jackson Creek Investment Advisors indicate strong market confidence in Corcept's growth potential.
  • The appointment of experienced leaders like Roberto Vieira and Monica Tellado suggests a strategic focus on expanding into oncology and emerging markets.
  • Corcept's commitment to patient and medical education enhances its reputation and fosters better patient outcomes.

What critics are saying

  • Ongoing legal disputes, such as the antitrust lawsuit from Teva, could result in financial and operational setbacks.
  • The loss of the Korlym patent lawsuit to Teva poses a significant threat to Corcept's revenue stream from its flagship product.

What makes Corcept Therapeutics unique

  • Corcept Therapeutics specializes exclusively in cortisol modulation, setting it apart from broader-focused biopharmaceutical companies.
  • Their flagship product, Korlym, is the first FDA-approved treatment for hypercortisolism in Cushing's syndrome, giving them a unique market position.
  • Corcept's extensive R&D pipeline with over 1,000 discovered selective cortisol modulators highlights their commitment to innovation in this niche field.